


Certificate of Analysis

Product	AMP-activated protein kinase $\alpha_1/\beta_1/\gamma_1$ (AMPK$\alpha_1/\beta_1/\gamma_1$), human recombinant, expressed in <i>E. coli</i>	
Cat No	PK-035-01	
Lot No	021014	
Description	<p>The human AMPK subunits α_1, β_1 and γ_1 were co-expressed in <i>E. coli</i> [1]. The α_1-subunit has a N-terminal maltose binding protein (MBP) tag. The heterotrimeric AMPK complex was purified using an amylose matrix. The catalytic subunit α_1 was activated by <i>in vitro</i> phosphorylation using CAMKK2. CAMKK2 and impurities were removed using HiLoad 16/600 Superdex 200 prep grade for size exclusion chromatography. The MBP-tag can be removed using TEV protease.</p> <p>Approved HUGO gene symbols: AMPK α_1: PRKAA1; AMPK β_1: PRKAB1; AMPK γ_1: PRKAG1</p> <p>Synonyms: 5' adenosine monophosphate-activated protein kinase</p>	
Quality	Protein concentration (Bradford with BSA as standard)	1.5 mg/ml
	Purity	> 95 % by SDS PAGE
	Specific activity * 1 Unit is defined as 1 picomole phosphate transferred to synthetic peptide AMARA (AMARAASAAALARRR) per min at 30 °C	4.300.000*/ mg
	Protease activity (Twining test)	none
Form	Liquid. 200 mM NaCl; 10 % (v/v) glycerol; 1 mM PMSF; 0.5 mM TCEP; 50 mM Tris /HCl pH 8.0, Complete (Roche, 1 tablet/50 ml)	
Package size	20 microgram	
Storage condition	-70 °C	
Shipment conditions	dry ice	

Material for in vitro research use only. Not for pharmaceutical or drug application. Material does not contain any animal products such as albumin.


AVOID FREEZE/THAW CYCLES

SDS-PAGE analysis



(Note: For AMPK β 1 is an anomalous electrophoretic mobility described in [2])

Activity Assay



Amino acid sequence information

MBP-AMPK α ₁: M393 corresponds to M1 of BC048980. Sequence based calculated M.W.: 105838.3 Da; TEV-cleavage site is underlined.

```

MKIEEGKLV I WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ 50
VAATGDGPD I IFWAHDRFGG YAQSGLLAEI TPKAFQDKL YPFTWDAVRY 100
NGKLIAYPI A VEALSLIYNK DLLPNPPKTW EEIPALDKEL KAKGKSALMF 150
NLQEPYFTW P LIAADGGYAF KYENKGYDIK DVGVDNAGAK AGLTFLVDLI 200
KNKHMNADT D YSIAEAAFNK GETAMTINGP WAWSNIDTSK VNYGVTVLPT 250
FKGQPSKPF V GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL 300
GAVALKSYE E ELAKDPRIAA TMENAQKGEI MPNIPQMSAF WYAVRTAVIN 350
AASGRQTV D E ALKDAQTNSS LNNNNNNNNN NLGENLYFQG GSMATAEKQK 400
HDGRVKIGH Y I LGDTLGVGT FGKVKVGKHE LTGHKVAVKI LNRQKIRSLD 450
VVGKIRREI Q NLKLFRRPHI IKLYQVISTP SDIFMVMEYV SGGELFDYIC 500
KNGRLDEK E S RRLFQQILSG VDYCHRHMVV HRDLKPEENVL LDAHMNAKIA 550
DFGLSNMMS D S GEFLRTSCGS PNYAAPEVIS GRLYAGPEVD IWSSGVILYA 600
LLCGTLPF D D DHVPTLFKKI CDGIFYTPQY LNPSVISLLK HMLQVDPMKR 650
    
```

ATIKDIREHE	WFKQDLPKYL	FPEDPSYSST	MIDDEALKEV	CEKFECSEEE	700
VLSCLYNRNH	QDPLAVAYHL	IIDNRRIMNE	AKDFYLATSP	PDSFLDDHHL	750
TRPHPERVPF	LVAETPRARH	TLDELNPQKS	KHQGVRKAKW	HLGIRSQSRP	800
NDIMAEVCRA	IKQLDYEWKV	VNPYYLRVRR	KNPVTSTYSK	MSLQLYQVDS	850
RTYLLDFRSI	DDEITEAKSG	TATPQRSGSV	SNYRSCQRSD	SDAEAQ GKSS	900
EVSLTSSVTS	LDSSPVDLTP	RPGSHTIEFF	EMCANLIKIL	AQ	942

AMPK β_1 : M1 corresponds to M1 of AJ224515.

Sequence based calculated M.W.: 30382.3 Da

MGNTSSERAA	LERHGGHKTP	RRDSSGGTKD	GDRPKILMDS	PEDADLFHSE	50
EIKAPEKEEF	LAWQHDLEVN	DKAPAQARPT	VFRWTGGGKE	VYLSGSFNNW	100
SKLPLTRSHN	NFVAILDLPE	GEHQYKFFVD	GQWTHDPSEP	IVTSQLGTVN	150
NIIQVKKTDF	EVFDALMVDS	QKCSDVSELS	SSPPGPYHQE	PYVCKPEERF	200
RAPPILPPHL	LQVILNKDTG	ISCDPALLPE	PNHVMLNHLY	ALSIKDGVMV	250
LSATHRYKKK	YVTTLLYKPI				270

AMPK γ_1 : M1 corresponds to M1 of U42412

Sequence based calculated M.W.: 37579.3 Da

METVISSDSS	PAVENEHPQE	TPESNNSVYT	SFMKSHRCYD	LIPTSSKLVV	50
FDTSLQVKKA	FFALVTNGVR	AAPLWDSKKQ	SFVGMLTITD	FINILHRYYK	100
SALVQIYELE	EHKIETWREV	YLQDSFKPLV	CISPNASLFD	AVSSLIRNKI	150
HRLPVIDPES	GNTLYILTHK	RILKFLKLF I	TEFPKPEFMS	KSLEELQIGT	200
YANIAMVRTT	TPVYVALGIF	VQHRVSALPV	VDEKGRVVDI	YSKFDVINLA	250
AEKTYNNLDV	SVTKALQHRS	HYFEGVLKCY	LHETLETIIN	RLVEAEVHRL	300
VVVDENDVVK	GIVSLSDILQ	ALVLTGGEKK	P		331

In vitro Kinase Assay

Assay Components

Assay Buffer (AB): 100 mM HEPES pH 7,5, 40 mM MgCl₂, 2 mM Na₃VO₄, 20 mM β-glycerophosphate, 0.04% CHAPS, 10 mM DTT, 600 mM AMP, Complete (Roche, 1 tablet/50 ml)

Dilution Buffer (DB): 20 mM Tris/HCl pH7,5, 0.01% CHAPS, 0.5 mM, Na₃VO₄, 2 mM DTT, 10% glycerol

Substrate: AMPK peptide AMARA, 800 μM.

Protein kinase: AMPK α₁/β₁/γ₁ Lot No 091014, 1,5 mg/mL, diluted to 0.5-1 ng/μL in DB directly before use.

Magnesium/ATP Cocktail: 75 mM MgCl₂, 500 μM ATP

Diluted [γ-³²P]ATP: Mix 197 μL Magnesium/ATP Cocktail with 3 μL(30 μCi) [γ-³²P]ATP (3,000 Ci/mmol, e.g. from Hartmann Analytic, Braunschweig, Germany)

Assay Procedure

All compounds are pipetted into a microcentrifuge tube on ice

1. Add 10 μL AB.
2. Add 10 μL 800 microM AMARA peptide.
3. Add 10 μL diluted AMPK α₁/β₁/γ₁, 5 – 10 ng/assay.
4. Add 10 μL of the diluted [γ-³²P]ATP.
5. Incubate 10 min at 30 °C.
6. Stop the reaction by setting samples on ice.
7. Remove 10 microliter and spot on P81 paper (let bind to the paper for 30 sec).
8. Immerse the paper in 85mM phosphoric acid. Shake gently on a rotator.
9. Wash 3 times for 5 minutes with phosphoric acid.
10. Wash briefly with acetone.
11. Dry under infrared light.
12. Count in a liquid scintillation counter.

References

- [1] Tan, S. (2001) A Modular Polycistronic Expression System for Overexpressing Protein Complexes in *Escherichia coli* Prot Expr Pur 21, 224-234
- [2] Neumann, D.; Woods, A.; Carling, D; Wallimann, T. and Uwe Schlattner, U. (2003) Mammalian AMP-activated protein kinase: functional, heterotrimeric complexes by co-expression of subunits in *Escherichia coli* Prot Expr Pur 30, 230–237